Home › Companies › TGTX

Tg Therapeutics

Market cap $9.48B 151.1M shares (10-Q, Nov 4, 2026) × $62.71 close Nov 17, 2026

Most recent annual filing: 2026-02-27

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. BRIUMVI (ublituximab) - supplemental BLA2H 2026BRIUMVI (ublituximab) - supplemental BLA, 2H 2026, material
  2. SubQ formulation Ph3 toplineyear-end 2026 / Q1 2027SubQ formulation Ph3 topline, year-end 2026 / Q1 2027, major
  3. ENHANCE single-infusion start commercial launchmid-2027ENHANCE single-infusion start commercial launch, mid-2027, routine
  4. Subcutaneous ublituximab commercial launch2028Subcutaneous ublituximab commercial launch, 2028, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Capital (as filed)

Cash
$429M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$75.3M Sep 30, 2026
Long-term investments
$56.0M Sep 30, 2026
Operating cash flow
$45.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$557M cash per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on Tg Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch TG Therapeutics (TGTX) — Scientific Deep Dive for BRIUMVI (ublituximab-xiiy) and Pipeline Products Elite commercial execution and a de-risked lead asset, but single-product concentration and a 2034 exclusivity clock at a price already reflecting most of the good news argue for waiting for a pullback toward the low-$30s.
  2. Watch UPDATE: TG Therapeutics (TGTX) - The SubQ Phase 1 De-Risk SubQ Phase 1 de-risks the Phase 3 odds but the stock has re-rated to $40 and the accumulation-on-pullbacks logic still applies; the year-end Phase 3 topline is the real inflection.
  3. Watch UPDATE: TG Therapeutics (TGTX) - A Billion-Dollar Run Rate and a Nickel of EPS Commercial execution is compounding faster than modeled but the stock is now above the level where chasing made sense, earnings quality is murkier, and the SubQ Phase 3 topline remains the event worth sizing around.
  4. Watch UPDATE: TG Therapeutics (TGTX) - The Wildcard Shows Its Face Azer-cel Phase 1 shows clean safety and CSF B-cell depletion upgrading it from near-zero to a real option, but efficacy data is uncontrolled and the stock has re-rated well above the original accumulation zone.
  5. Watch UPDATE: TG Therapeutics (TGTX) - The Nickel Became Thirty-Five Cents Q3 earnings quality improved with 33% operating margin and guidance raised to ~$1B, but U.S. sales flattened sequentially, a new tariff emerged, and the valuation has stretched to ~10x sales ahead of the SubQ readout.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (21)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 29, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

3 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)